These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches. Shea M; Costa DB; Rangachari D Ther Adv Respir Dis; 2016 Apr; 10(2):113-29. PubMed ID: 26620497 [TBL] [Abstract][Full Text] [Related]
3. Beyond EGFR and ALK inhibition: unravelling and exploiting novel genetic alterations in advanced non small-cell lung cancer. Califano R; Abidin A; Tariq NU; Economopoulou P; Metro G; Mountzios G Cancer Treat Rev; 2015 May; 41(5):401-11. PubMed ID: 25842168 [TBL] [Abstract][Full Text] [Related]
4. [Driver genes expression and clinical characteristics of targeted therapy in non-small cell lung cancer in Yunnan-Kweichow Plateau]. Lin YP; Li Q; Ma LY; Liu X; Dai M; Wang XX; Li HS; Liu JX; Shen ZH; Guo YJ; Du YX; Yang RJ; Huang YC; Zhou YC Zhonghua Zhong Liu Za Zhi; 2020 Sep; 42(9):735-740. PubMed ID: 32988155 [No Abstract] [Full Text] [Related]
5. Novel Emerging Molecular Targets in Non-Small Cell Lung Cancer. Rebuzzi SE; Zullo L; Rossi G; Grassi M; Murianni V; Tagliamento M; Prelaj A; Coco S; Longo L; Dal Bello MG; Alama A; Dellepiane C; Bennicelli E; Malapelle U; Genova C Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33807876 [TBL] [Abstract][Full Text] [Related]
6. Treatment of advanced non-small-cell lung cancer with epidermal growth factor receptor (EGFR) mutation or ALK gene rearrangement: results of an international expert panel meeting of the Italian Association of Thoracic Oncology. Gridelli C; de Marinis F; Cappuzzo F; Di Maio M; Hirsch FR; Mok T; Morgillo F; Rosell R; Spigel DR; Yang JC; Ciardiello F Clin Lung Cancer; 2014 May; 15(3):173-81. PubMed ID: 24486058 [TBL] [Abstract][Full Text] [Related]
7. Emergence of RET rearrangement co-existing with activated EGFR mutation in EGFR-mutated NSCLC patients who had progressed on first- or second-generation EGFR TKI. Klempner SJ; Bazhenova LA; Braiteh FS; Nikolinakos PG; Gowen K; Cervantes CM; Chmielecki J; Greenbowe JR; Ross JS; Stephens PJ; Miller VA; Ali SM; Ou SH Lung Cancer; 2015 Sep; 89(3):357-9. PubMed ID: 26187428 [TBL] [Abstract][Full Text] [Related]
8. Targeted therapy for NSCLC with driver mutations. Minuti G; D'Incecco A; Cappuzzo F Expert Opin Biol Ther; 2013 Oct; 13(10):1401-12. PubMed ID: 23930754 [TBL] [Abstract][Full Text] [Related]
9. [Research Progress of Targeted Therapy for BRAF Mutation in Advanced Non-small Cell Lung Cancer]. Liu X; Zhong D Zhongguo Fei Ai Za Zhi; 2018 Aug; 21(8):635-640. PubMed ID: 30172272 [TBL] [Abstract][Full Text] [Related]
10. Targeting the MET gene for the treatment of non-small-cell lung cancer. Gelsomino F; Facchinetti F; Haspinger ER; Garassino MC; Trusolino L; De Braud F; Tiseo M Crit Rev Oncol Hematol; 2014 Feb; 89(2):284-99. PubMed ID: 24355409 [TBL] [Abstract][Full Text] [Related]
11. New Targets in Non-Small Cell Lung Cancer. Park SJ; More S; Murtuza A; Woodward BD; Husain H Hematol Oncol Clin North Am; 2017 Feb; 31(1):113-129. PubMed ID: 27912827 [TBL] [Abstract][Full Text] [Related]
12. Emerging treatment for advanced lung cancer with EGFR mutation. Inal C; Yilmaz E; Piperdi B; Perez-Soler R; Cheng H Expert Opin Emerg Drugs; 2015; 20(4):597-612. PubMed ID: 26153235 [TBL] [Abstract][Full Text] [Related]
13. Molecular Mechanisms and Targeted Therapies Including Immunotherapy for Non-Small Cell Lung Cancer. Nagano T; Tachihara M; Nishimura Y Curr Cancer Drug Targets; 2019; 19(8):595-630. PubMed ID: 30526458 [TBL] [Abstract][Full Text] [Related]